Top of page

Student/Staff Portal
Global Site Navigation

School of Medical and Health Sciences

Local Section Navigation
You are here: Main Content
  • Photo of Dr Leslie Beasley in white and floral jacket

    Dr Leslie Beasley

Related Contents

  • See Also
  • ORCID iD
    http://orcid.org/0000-0001-7595-6523
  • ORCID iD

Dr Leslie Beasley

Post Doctoral Research Fellow

Staff Member Details
Telephone: +61 8 6304 2816
Email: l.calapre@ecu.edu.au
Campus: Joondalup  
Room: JO17.310  

Dr Leslie Beasley is a Postdoctoral Research Fellow in the Cancer research program within the ECU Centre for Precision Health.

Research Areas and Interests

  • Liquid Biopsy for Melanoma
  • Circulating Tumour DNA
  • Environmental stressors and skin cancers

Qualifications

  • Doctor of Philosophy, Edith Cowan University, 2015.
  • Bachelor of Science Human Biology (Honours), Edith Cowan University, 2011.
  • Bachelor of Science (Biomedical Science), Edith Cowan University, 2010.

Research Outputs

2023

Journal Articles

  • Abed, A., Beasley, A., Reid, A., Law, N., Beasley, L., Millward, M., Lo, J., Gray, E. (2023). Circulating pre-treatment T-cell receptor repertoire as a predictive biomarker in advanced or metastatic non-small-cell lung cancer patients treated with pembrolizumab alone or in combination with chemotherapy. ESMO Open, 8(6), Article number 102066. https://doi.org/10.1016/j.esmoop.2023.102066.
  • Warburton, L., Reid, A., Amanuel, B., Beasley, L., Millward, M., Gray, E. (2023). Detectable ctDNA at the time of treatment cessation of ipilimumab and nivolumab for toxicity predicts disease progression in advanced melanoma patients. Frontiers in Oncology, 13(Article in press), Article number 1280730. https://doi.org/10.3389/fonc.2023.1280730.
  • Beasley, A., De Bruyn, D., Beasley, L., Al-Ogaili, Z., Isaacs, T., Bentel, J., Reid, A., Dwarkasing, R., Pereira, M., Khattak, A., Meniawy, T., Millward, M., Brosens, E., De Klein, A., Chen, F., Kiliҫ, E., Gray, E. (2023). Detection of metastases using circulating tumour DNA in uveal melanoma. Journal of Cancer Research and Clinical Oncology, 2023(Article in press), 11 pages. https://doi.org/10.1007/s00432-023-05271-3.

2022

Journal Articles

  • Dyke, J., Beasley, L., Beasley, A., Gray, E., Allcock, R., Bentel, J. (2022). Application of multiplex ligation-dependent probe amplification (MLPA) and low pass whole genome sequencing (LP-WGS) to the classification / characterisation of low grade glioneuronal tumours. Pathology, Research and Practice, 229(January 2022), Article number 153724. https://doi.org/10.1016/j.prp.2021.153724.
  • Abed, A., Law, N., Beasley, L., Lo, J., Bhat, V., Bowyer, S., Millward, M., Gray, E. (2022). Human leucocyte antigen genotype association with the development of immune-related adverse events in patients with non-small cell lung cancer treated with single agent immunotherapy. European Journal of Cancer, 172(Sept 2022), 98-106. https://doi.org/10.1016/j.ejca.2022.05.021.
  • Marsavela, G., McEvoy, A., Pereira, M., Reid, A., Al-Ogaili, Z., Warburton, L., Khattak, A., Abed, A., Meniawy, T., Millward, M., Ziman, M., Beasley, L., Gray, E. (2022). Detection of clinical progression through plasma ctDNA in metastatic melanoma patients: a comparison to radiological progression. British Journal of Cancer, 126(3), 401-408. https://doi.org/10.1038/s41416-021-01507-6.

2021

Book Chapters

  • Marsavela, G., Reid, A., Gray, E., Beasley, L. (2021). Isolation and quantification of plasma circulating tumor DNA from melanoma patients. Melanoma. Methods and Protocols (247-263). Humana Press. https://doi.org/10.1007/978-1-0716-1205-7_19.

Journal Articles

  • Mavropalias, G., Beasley, L., Morici, M., Koeda, T., Poon, W., Barley, O., Gray, E., Blazevich, T., Nosaka, K. (2021). Changes in plasma hydroxyproline and plasma cell‑free DNA concentrations after higher‑ versus lower‑intensity eccentric cycling. European Journal of Applied Physiology, 121(4), 1087-1097. https://doi.org/10.1007/s00421-020-04593-1.
  • Lin, W., Beasley, A., Ardakani, N., Denisenko, E., Beasley, L., Jones, M., Wood, B., Warburton, L., Forrest, A., Gray, E. (2021). Intra- and inter-tumoral heterogeneity of liver metastases in a patient with uveal melanoma revealed by single-cell RNA sequencing. Cold Spring Harbor Molecular Case Studies, 7(5), article number a006111. https://doi.org/10.1101/mcs.a006111.
  • Vasantharajan, S., Eccles, M., Rodger, E., Pattison, S., McCall, J., Gray, E., Beasley, L., Chatterjee, A. (2021). The epigenetic landscape of circulating tumour cells. Biochimica et Biophysica Acta: Reviews on Cancer, 1875(2), Article number 188514. https://doi.org/10.1016/j.bbcan.2021.188514.
  • Asante, D., Morici, M., Mohan, G., Acheampong, E., Spencer, I., Lin, W., Van Miert, P., Gibson, S., Beasley, A., Ziman, M., Beasley, L., Meniawy, T., Gray, E. (2021). Multi-Marker Immunofluorescent Staining and PD-L1 Detection on Circulating Tumour Cells from Ovarian Cancer Patients. Cancers, 13(24), Article number 6225. https://doi.org/10.3390/cancers13246225.
  • Beasley, A., Isaacs, T., Vermeulen, T., Freeman, J., Desousa, J., Bhikoo, R., Hennessy, D., Reid, A., Chen, F., Bentel, J., McKay, D., Conway, R., Pereira, M., Mirzai, B., Beasley, L., Erber, W., Ziman, M., Gray, E. (2021). Analysis of Circulating Tumour Cells in Early-Stage Uveal Melanoma: Evaluation of Tumour Marker Expression to Increase Capture. Cancers, 13(23), Article 5990. https://doi.org/10.3390/cancers13235990.

2020

Journal Articles

  • Warburton, L., Meniawy, T., Beasley, L., Pereira, M., McEvoy, A., Ziman, M., Gray, E., Millward, M. (2020). Stopping targeted therapy for complete responders in advanced BRAF mutant melanoma. Scientific Reports, 10(1), Article number 18878. https://doi.org/10.1038/s41598-020-75837-5.
  • Warburton, L., Beasley, L., Pereira, M., Reid, A., Robinson, C., Amanuel, B., Ziman, M., Millward, M., Gray, E. (2020). Circulating Tumour DNA in Advanced Melanoma Patients Ceasing PD1 Inhibition in the Absence of Disease Progression. Cancers, 12(11), Article number 3486. https://doi.org/10.3390/cancers12113486.
  • Marsavela, G., Johansson, P., Pereira, M., McEvoy, A., Reid, A., Robinson, C., Warburton, L., Khattak, A., Meniawy, T., Amanuel, B., Millward, M., Hayward, N., Ziman, M., Gray, E., Beasley, L. (2020). The Prognostic Impact of Circulating Tumour DNA in Melanoma Patients Treated with Systemic Therapies-Beyond BRAF Mutant Detection. Cancers, 12(12), Article number 3793. https://doi.org/10.3390/cancers12123793.
  • Beasley, A., Bentel, J., Allcock, R., Vermeulen, T., Beasley, L., Isaacs, T., Ziman, M., Chen, F., Gray, E. (2020). Low-Pass Whole-Genome Sequencing as a Method of Determining Copy Number Variations in Uveal Melanoma Tissue Samples. The Journal of Molecular Diagnostics, 22(3), 429-434. https://doi.org/10.1016/j.jmoldx.2019.12.005.
  • Abed, A., Beasley, L., Lo, J., Correia, S., Bowyer, S., Chopra, A., Watson, M., Khattak, A., Millward, M., Gray, E. (2020). Prognostic value of HLA-I homozygosity in patients with non-small cell lung cancer treated with single agent immunotherapy. Journal for ImmunoTherapy of Cancer, 8(2), Article number e001620. https://doi.org/10.1136/jitc-2020-001620.
  • Aya-Bonilla, C., Morici, M., Hong, X., McEvoy, A., Sullivan, R., Freeman, J., Beasley, L., Khattak, A., Meniawy, T., Millward, M., Ziman, M., Gray, E. (2020). Detection and prognostic role of heterogeneous populations of melanoma circulating tumour cells. British Journal of Cancer, 122(7), 1059-1067. https://doi.org/10.1038/s41416-020-0750-9.
  • Marsavela, G., Lee, J., Beasley, L., Wong, S., Pereira, M., McEvoy, A., Reid, A., Robinson, C., Warburton, L., Abed, A., Khattak, A., Meniawy, T., Dawson, S., Sandhu, S., Carlino, M., Menzies, A., Scolyer, R., Long, G., Amanuel, B., Millward, M., Ziman, M., Rizos, H., Gray, E. (2020). Circulating Tumor DNA Predicts Outcome from First-, but not Second-line Treatment and Identifies Melanoma Patients Who May Benefit from Combination Immunotherapy. Clinical Cancer Research, 26(22), 5926-5933. https://doi.org/10.1158/1078-0432.CCR-20-2251.
  • Clark, M., Rizos, H., Pereira, M., McEvoy, A., Marsavela, G., Beasley, L., Meehan, K., Ruhen, O., Khattak, A., Meniawy, T., Long, G., Carlino, M., Menzies, A., Millward, M., Ziman, M., Gray, E. (2020). Detection of BRAF splicing variants in plasma-derived cell-free nucleic acids and extracellular vesicles of melanoma patients failing targeted therapy therapies. Oncotarget, 11(44), 4016-4027. https://doi.org/10.18632/oncotarget.27790.
  • Asante, D., Beasley, L., Ziman, M., Meniawy, T., Gray, E. (2020). Liquid biopsy in ovarian cancer using circulating tumor DNA and cells: Ready for prime time?. Cancer Letters, 468(1 January 2020), 59-71. https://doi.org/10.1016/j.canlet.2019.10.014.

2019

Journal Articles

  • Gray, E., Witkowski, T., Pereira, M., Beasley, L., Herron, K., Irwin, D., Chapman, B., Khattak, A., Raleigh, J., Hatzimihalis, A., Cebon, J., Sandhu, S., McArthur, G., Millward, M., Ziman, M., Dubrovic, A., Wong, S. (2019). Genomic Analysis of Circulating Tumor DNA Using a Melanoma-Specific UltraSEEK Oncogene Panel. The Journal of Molecular Diagnostics, 21(3), 418-426. https://doi.org/10.1016/j.jmoldx.2018.12.001.
  • Beasley, L., Warburton, L., Millward, M., Gray, E. (2019). Circulating tumour DNA (ctDNA) as a biomarker in metachronous melanoma and colorectal cancer- a case report. BMC Cancer, 19(1), Article number 1109. https://doi.org/10.1186/s12885-019-6336-3.
  • Beasley, L., Giardina, T., Robinson, C., Reid, A., Al-Ogaili, Z., Pereira, M., McEvoy, A., Warburton, L., Hayward, N., Khattak, A., Meniawy, T., Millward, M., Amanuel, B., Ziman, M., Gray, E. (2019). Locus-specific concordance of genomic alterations between tissue and plasma circulating tumor DNA in metastatic melanoma. Molecular Oncology, 13(2), 171-184. https://doi.org/10.1002/1878-0261.12391.

2018

Journal Articles

  • Beasley, A., Isaacs, T., Khattak, A., Freeman, J., Allcock, R., Chen, F., Pereira, M., Yau, K., Bentel, J., Vermeulen, T., Beasley, L., Millward, M., Ziman, M., Gray, E. (2018). Clinical Application of Circulating Tumor Cells and Circulating Tumor DNA in Uveal Melanoma. JCO Precision Oncology, 2(May 17, 2018), 12p.. https://doi.org/10.1200/PO.17.00279.
  • McEvoy, A., Warburton, L., Al-Ogaili, Z., Celliers, L., Beasley, L., Pereira, M., Khattak, A., Meniawy, T., Millward, M., Ziman, M., Gray, E. (2018). Correlation between circulating tumour DNA and metabolic tumour burden in metastatic melanoma patients. BMC Cancer, 18(1), Article no. 726. https://doi.org/10.1186/s12885-018-4637-6.

2017

Journal Articles

  • Beasley, L., Warburton, L., Millward, M., Ziman, M., Gray, E. (2017). Circulating tumour DNA (ctDNA) as a liquid biopsy for melanoma. Cancer Letters, 404(28 Sept, 2017), 62-69. https://doi.org/10.1016/j.canlet.2017.06.030.
  • Beasley, L., Gray, E., Kurdykowski, S., David, A., Descargues, P., Ziman, M. (2017). SIRT1 activation mediates heat-induced survival of UVB damaged Keratinocytes. BMC Dermatology, 17(June 2017), Article No. 8. https://doi.org/10.1186/s12895-017-0060-y.
  • McEvoy, A., Beasley, L., Pereira, M., Giardina, T., Robinson, C., Khattak, M., Meniawy, T., Pritchard, A., Hayward, N., Amanuel, B., Millward, M., Ziman, M., Gray, E. (2017). Sensitive droplet digital PCR method for detection of TERT promoter mutations in cell free DNA from patients with metastatic melanoma. Oncotarget, 8(45), 78890-78900. https://doi.org/10.18632/oncotarget.20354.

2016

Journal Articles

  • Beasley, L., Gray, E., Kurdykowski, S., David, A., Hart, P., Descargues, P., Ziman, M. (2016). Heat-mediated reduction of apoptosis in UVB-damaged keratinocytes in vitro and in human skin ex vivo. BMC Dermatology, 16(1), Article no. 6. https://doi.org/10.1186/s12895-016-0043-4.

2015

Journal Articles

  • Gray, E., Reid, A., Bowyer, S., Beasley, L., Siew, K., Pearce, R., Cowell, L., Frank, M., Millward, M., Ziman, M. (2015). Circulating Melanoma Cell Subpopulations: Their Heterogeneity and Differential Responses to Treatment. Journal of Investigative Dermatology, 135(8), 2040-2048. https://doi.org/10.1038/jid.2015.127.

2013

Journal Articles

Research Projects

  • Western Australia Melanoma Initiative (WAMI): developing novel treatments for immunotherapy-resistant melanoma, Cancer Research Trust, The Grant, 2024 ‑ 2029, $1,167,284.
  • Fragmentomic features of cell-free DNA predict late-stage melanoma treatment benefit and survival, Spinnaker Health Research Foundation, Early Career Research Grant, 2025 ‑ 2027, $20,000.
  • Identification of melanoma-specific signature that can predict response to immunotherapies., Cancer Council of WA Inc, Suzanne Cavanagh Early Career Investigator Grants, 2021 ‑ 2023, $34,960.
  • Circulating tumour DNA as a biomarker of treatment response for patients with advanced high grade serous ovarian cancer receiving neoadjuvant chemotherapy with and without durvalumab and tremilimumab as part of the iprime study, Australia New Zealand Gynaecological Oncology Group (ANZGOG), Grant, 2020 ‑ 2021, $49,317.
  • Genomic HLA heterozygosity, T-cell receptor (TCR) – repertoire diversity and tumor PD-L1 expression as predictive biomarkers of response to immunotherapy in lung cancer patients, Lung Foundation Australia, Ellen Yates Memorial Grant in Aid, 2020 ‑ 2021, $20,000.
  • Enhancing Methodologies for Circulating Tumour DNA (ctDNA) Analysis, Edith Cowan University, ECU Early Career Researcher Grant - 2017, 2017 ‑ 2018, $30,000.

Research Student Supervision

Current Supervisions

Associate Supervisor

  • Doctor of Philosophy, Extracellular vesicles as tumour-specific biomarkers of melanoma and lung cancer
  • Doctor of Philosophy, Liquid Biopsy to assess microscopic residual disease in Melanoma

Completed Supervisions

Associate Supervisor

  • Doctor of Philosophy, Assessment of the clinical utility of ctDNA analysis for melanoma management
  • Doctor of Philosophy, Unravelling the potential applications of extracellular vesicles for the clinical management of melanoma patients
  • Doctor of Philosophy, Genomic HLA and pre-treatment TCR repertoire as non-invasive biomarkers of clinical outcome to immunotherapy in advanced non-small cell lung cancer patients
  • Doctor of Philosophy, Blood Based Biomarkers of Response to Immunotherapy in Advanced Melanoma
Skip to top of page